ImmunityBio (IBRX) Capital Expenditures Growth (3y) (2017 - 2026)
ImmunityBio (IBRX) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ImmunityBio | 7.60 Bn | 7.22 Bn | 43.97 Mn | -61.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.91% |
| Dec 31, 2025 | -65.28% |
| Sep 30, 2025 | -28.12% |
| Jun 30, 2025 | -62.98% |
| Dec 31, 2024 | -61.75% |
| Sep 30, 2024 | 40.32% |
| Jun 30, 2024 | 201.84% |
| Mar 31, 2024 | -33.39% |
| Dec 31, 2023 | -95.93% |
| Jun 30, 2023 | -44.85% |
| Mar 31, 2023 | 272.92% |
| Dec 31, 2022 | 234.24% |
| Sep 30, 2022 | 93.66% |
| Jun 30, 2022 | 220.68% |
| Mar 31, 2022 | -132.85% |
| Dec 31, 2021 | -34.33% |
| Sep 30, 2021 | -43.95% |
| Jun 30, 2021 | -26.56% |
| Mar 31, 2021 | -4.52% |
| Dec 31, 2020 | -556.28% |